🇺🇸 Metoprolol- Toprol XL in United States

29 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 29

Most-reported reactions

1. Gastrointestinal Haemorrhage — 5 reports (17.24%)
2. Fatigue — 4 reports (13.79%)
3. Asthenia — 3 reports (10.34%)
4. Fall — 3 reports (10.34%)
5. Subdural Haematoma — 3 reports (10.34%)
6. Type 2 Diabetes Mellitus — 3 reports (10.34%)
7. Abdominal Discomfort — 2 reports (6.9%)
8. Chest Discomfort — 2 reports (6.9%)
9. Chest Pain — 2 reports (6.9%)
10. Condition Aggravated — 2 reports (6.9%)

Source database →

Frequently asked questions

Is Metoprolol- Toprol XL approved in United States?

Metoprolol- Toprol XL does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Metoprolol- Toprol XL in United States?

AstraZeneca is the originator. The local marketing authorisation holder may differ — check the official source linked above.